Kesarla Rajesh

Kesarla Rajesh

Auto-generated profile, based on publicly available information

Kesarla Rajesh

Department of Pharmaceutical Technology, Parul Institute of Pharmacy, Parul University, Vadodara, Gujarat, 391760, India

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2026 in Recent Advances in Drug Delivery and Formulation
Verified
Journal Article
Closed access
PDF file
SGShayeri Chatterjee Ganguly
Shayeri Chatterjee Ganguly
PMPriya Manna
Priya Manna
SBSatadeep Bandyapadhyay
Satadeep Bandyapadhyay
DKDipanjan Karati
Dipanjan Karati
NRNiladri Sekhar Roy
Niladri Sekhar Roy
BBBikash Banerjee
Bikash Banerjee
Lipid Nanoparticles (LNPs) have emerged as adaptable and effective delivery systems for RNA-based therapies, transforming contemporary medicine. This article covers the design, processes, and therapeutic potential of LNPs for RNA delivery. LNPs improve RNA encapsulation, stability, and targeted cellular delivery. Lipid nanoparticles protect RNA molecules from enzymatic degradation, enable endosomal escape, and allow cytoplasmic release for gene control or functional translation. Various RNA types are delivered using LNPs for specific therapeutic applications, such as mRNA for vaccines and protein replacement, siRNA for gene silencing in diverse genetic and oncological conditions, miRNA for gene expression modulation, and CRISPR/Cas9 components for targeted gene editing. LNP-mediated RNA therapies have demonstrated efficacy across a diverse array of diseases. The design and optimization of LNPs depend on several factors. In vivo studies and preclinical models have confirmed their safety and efficacy, leading to successful clinical trials and FDA-approved RNAbased therapies. However, challenges encompass immunogenicity, limited tissue selectivity, substantial production requirements, and longer safety duration. Recent advancements in ionizable lipid chemistry, microfluidic formulation, and targeted delivery techniques are broadening the therapeutic potential of LNPs, reinforcing their significance as essential carriers in the forthcoming era of precision RNA medicine.

21 May 2026 in Food Biomacromolecules
Verified
Journal Article
Open access
PDF file
SSSridevi Shanmugam
Sridevi Shanmugam
RBRukaiah Fatma Begum
Rukaiah Fatma Begum
NSNirenjen Shanmugasundaram
Nirenjen Shanmugasundaram
Bhupendra G PrajapatiBhupendra G Prajapati
Bhupendra G Prajapati
SSSuresh Ankul Singh
Suresh Ankul Singh
KRKesarla Rajesh
Kesarla Rajesh
Cardiovascular diseases (CVDs) remain the leading cause of global mortality, necessitating effective preventive and adjunct therapeutic strategies beyond conventional pharmacological interventions. Although previous reviews have focused on individual nutrients or dietary patterns, this review provides a mechanism‐based, integrative perspective on food‐grade proteins, lipids, and dietary fibers in CVDs. Here, food‐grade refers to nutritionally safe, regulatory‐compliant macronutrients incorporated into functional foods with defined physiological benefits. This review evaluates how these macronutrients target key CVD pathways. Food‐grade proteins release bioactive peptides with ACE‐inhibitory, lipid‐lowering, and endothelial‐protective effects. Functional lipids, particularly omega‐3 fatty acids and phytosterols, regulate lipid metabolism, stabilize atherosclerotic plaques, and reduce inflammation. Soluble dietary fibers such as β‐glucan, psyllium, and pectin lower cholesterol absorption, improve glycemic control, and modulate gut microbiota. Importantly, this review highlights synergistic and antagonistic interactions among these macronutrients within real food matrices, emphasizing their combined influence on digestion, bioavailability, and metabolic responses. Dose–response relationships and practical intake considerations are also discussed to bridge mechanistic insights with dietary applications. Collectively, this framework positions food‐grade macronutrients as interactive modulators of cardiovascular health rather than isolated components. Future research should focus on validating nutrient interactions, optimizing synergistic formulations, and establishing clinically effective intake thresholds.

28 October 2026 in Recent Advances in Drug Delivery and Formulation
Verified
Journal Article
Closed access
PDF file
PKPiyali Khamkat
Piyali Khamkat
BCBramhajit Chatterjee
Bramhajit Chatterjee
SRSneha Roy
Sneha Roy
SMSahana Mozumdar
Sahana Mozumdar
SDSrija Das
Srija Das
SMSwarupananda Mukherjee
Swarupananda Mukherjee
Driven by demand for new materials with intriguing features, the discipline of materials science and technology is rapidly advancing and now makes a significant contribution to research in nanoscale science. A material is classified based on the number of dimensions outside the nanoscale range in which particles are contained. Artificial nanocrystals with confinement in all three dimensions and nanometer-scale electron-transport capabilities are called quantum dots (QDs). Because of their distinct physical and optical properties, QDs have captivated scientists worldwide since their discovery in 1981. Their potential for use in a variety of optical-based biological applications makes them extremely desirable. QDs, which are nanocrystals smaller than 10 nm, possess unique optical, electrical, and chemical properties due to quantum confinement. QDs can be synthesised via colloidal, hydrothermal, and biomimetic methods. They have potential uses in biosensors, bioimaging, wastewater treatment, drug delivery, and quantum computing. QDs’ basic composition, size, surface functionalization, and dose are the primary variables affecting their biocompatibility and toxicity. Potential toxicity from oxidative stress and heavy metal release can be significantly reduced by using appropriate surface coating and encapsulation techniques. In 2011, the first human clinical trial using QD technology was approved by the USFDA. This innovative phase I exploratory trial used silica-based near-infrared QDs in a small number of patients with melanoma. This review provides a basic introduction to QDs, their preparation process, drug release mechanism, applications, challenges, toxicity concerns, and clinical trials. The role of artificial intelligence (AI), machine learning (ML), and deep learning in QD design, optimization, biocompatibility enhancement, and augmentation of therapeutic performance has been the focus, leading to a novel perspective.